ANN ARBOR, Mich.--(BUSINESS WIRE)--Essen BioScience, Inc. (“Essen” or the Company), a leading provider of critical analytical instrumentation, software, reagents and services used in cell-based life science research, is pleased to announce that Jim Ryder will join the leadership team as Essen’s new Global Head of Sales.
Jim Ryder is a veteran sales, marketing and operations executive with more than 20 years of experience expanding and building new revenue streams for technology businesses. Jim was most recently the Vice President of Sales and Marketing at Advanced Microscopy Group (AMG), now a subsidiary Thermo Fischer Scientific (formerly Life Technologies). AMG is the provider of the EVOS® line of imaging systems used in cell-based life sciences research. At AMG, Jim was instrumental in developing and implementing strategies to improve sales force effectiveness, developing new sales opportunities, initiating and executing marketing efforts and launching new product lines. Prior to AMG, Jim was the Senior Vice President of Sales and Distribution at Clearwire where he was responsible for all revenue in the direct go to market channels and helped prepare the company for its IPO in 2006. Previously, he was the COO for Nextel Partners, one of the leading growth companies in the cellular industry which ultimately led to its acquisition by Sprint.
“I am excited that Jim has joined us at Essen,” said Brett Williams. “Jim has proven capabilities in building and leading world-class customer-focused sales and marketing organizations. I am confident that he will play a critical role in helping Essen reach new customers and serve our existing customers better.”
“I have great respect for Brett and the rest of the management team at Essen and I’m thrilled to join them. The Company offers a unique set of solutions that are changing the way the world conducts cell-based life sciences research and I’m extremely excited in leading the efforts to bring Essen’s set of instrumentation, software and reagents to a broad set of customers in the life sciences research world,” said Mr. Ryder.
About Essen BioScience, Inc.
Essen BioScience, based in Ann Arbor, MI, is a leading provider of critical analytical instrumentation, software, reagents and services used in cell-based life sciences research. Essen was founded in 1999 by Kirk Schroeder and Brad Neagle who have previously been responsible for “best/first in class” innovations in the field of cell-based in-vitro assays and instrumentation with FLIPR in 1994 and IonWorks in 2002. Essen’s flagship product, the IncuCyte ZOOMTM live-content imaging system, provides researchers unparalleled access to quantitative, kinetic cellular biology while improving data quality and streamlining image collection through automation of the cell analysis process. The IncuCyte is used at hundreds of locations across the world in labs focused on cell production, microscopy/ imaging, assay development and screening. The technology is applicable to almost every cell-based research area including oncology, stem-cell science, and neurobiology. Essen serves the leading biopharmaceutical, academic and research institutions around the globe through offices in Michigan, the United Kingdom and Japan. For more information, please visit http://www.essenbioscience.com
About SFW Capital Partners
SFW Capital Partners is the leading investor in analytical tools and related services companies, including providers of instrumentation, software, information and business services. Our 20+ years of knowledge of the relevant business models, technology, competitive dynamics and service requirements gives us a unique ability to support management teams in growing their companies and building value. For more information, please visit www.sfwcap.com
